Saturday 17 October 2026
Export NRSN’s income statement to Excel — free account
NeuroSense Therapeutics Ltd.
NRSN Healthcare Biotechnology
Insiders bought in the last twelve months.
3.07
0.10
−3.15%
Follow NRSN
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 2.39 | 1.15 | 0.40 | 0.51 | 0.68 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 4.70 | 8.18 | 2.91 | 2.33 | 2.60 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 3 | 11 | 14 | 18 | 15 | 16 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | (1) | (3) | (4) | (12) | (10) | (10) | (11) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (1) | (3) | (4) | (12) | (10) | (10) | (11) | |||||
| Depreciation | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (5.27) | (10.25) | (13.00) | (21.40) | (16.60) | (10.80) | (8.80) | |||||
| Cash flow | — | — | — | (2.51) | (2.52) | (4.93) | (13.19) | (12.25) | (10.90) | (6.02) | |||||
| Capex | — | — | — | (0.03) | (0.03) | (0.05) | (0.12) | (0.04) | 0.00 | (0.01) | |||||
| Free cash flow | — | — | — | (2.54) | (2.55) | (4.98) | (13.31) | (12.29) | (10.90) | (6.03) | |||||
| Book value | — | — | — | 3.96 | 2.39 | 28.85 | 9.77 | (2.58) | 2.78 | (1.22) | |||||
| Shares, m | — | — | — | 0 | 0 | 0 | 1 | 1 | 1 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (1) | (1) | (2) | (8) | (8) | (10) | (8) | ||||
| Capex | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | — | (1) | (1) | (2) | (8) | (8) | (10) | (8) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 1 | 1 | 11 | 6 | (1) | 2 | (2) | ||||
| Total debt | — | — | — | — | — | — | 0 | 0 | — | 0 | |||||
| Net debt | — | — | — | (1) | (1) | (11) | (7) | (3) | (3) | 0 | |||||
| Shareholders’ equity | — | — | — | 1 | 1 | 9 | 6 | (2) | 3 | (2) | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (255.92) | (326.18) | (66.19) | (128.94) | (185.53) | (263.14) | (397.11) | ||||
| ROIC | — | — | — | (3,355.98) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 0.00 | (358.66) | (83.62) | (168.75) | (523.68) | (2,478.16) | (2,174.98) | |||||
Negative figures in brackets.
Fundamentals updated 2 Oct 2026
Charts ten years each
NeuroSense Therapeutics Ltd. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TCRT Alaunos Therapeutics, Inc. | $6.4M | — (loss-making) | — (loss-making) | +200.00% (above 0%: growing) | n/m | +57.20% (above 0%: growing) | 100.00% | 0.00% | Compare |
| EVGN Evogene Ltd. | $6.3M | — (loss-making) | — (loss-making) | −35.02% (below 0%: shrinking) | n/m | +17.72% (above 0%: growing) | 40.63% | (738.62%) | Compare |
| LEXX Lexaria Bioscience Corp. | $6.3M | — (loss-making) | — (loss-making) | −89.12% (below 0%: shrinking) | n/m | +53.90% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ENVB Enveric Biosciences, Inc. | $6.2M | — (loss-making) | — (loss-making) | −7.28% (below 0%: shrinking) | n/m | −29.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| TRAW Traws Pharma, Inc. | $6.2M | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −25.51% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALZN Alzamend Neuro, Inc. | $6.2M | — (loss-making) | — | — | n/m | +51.82% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NRSN NeuroSense Therapeutics Ltd. | $6.0M | — (loss-making) | — | — | n/m | −23,458.82% (below 0%: shrinking) | — | 0.00% | |
| IMNN Imunon, Inc. | $6.0M | — (loss-making) | — (loss-making) | 0.00% | n/m | −4.24% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ORGS Orgenesis Inc. | $5.7M | — (loss-making) | 1.0× | +82.42% (above 0%: growing) | n/m | −317.93% (below 0%: shrinking) | 2,780.73% | (6,044.52%) | Compare |
| Median of peers | $6.2M | — | — | −7.28% | — | +6.74% | 20.32% | 0.00% |
NeuroSense Therapeutics Ltd. (NRSN) key facts
- NeuroSense Therapeutics Ltd. (NRSN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, NRSN traded at $3.07, a market capitalization of $6.0 million.
- Return on equity was −2,175.0% and debt-to-equity 0.00.